CMMB - Earnings announcements

TEL AVIV, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its third quarter 2024 financial results and providing a business update on November 14, 2024, at 7:00 am Eastern Time.   Investors who would like to discuss the financial results or business update after the press release has been issued are invited to contact the company at IR@chemomab.com. About Chemomab Therapeutics Ltd.                                                     

TEL AVIV, Israel, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) ("Chemomab" or the "Company"), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its second quarter 2024 financial results and providing a business update on August 21, 2024, at 7:00 am Eastern Time.   Investors who would like to discuss the financial results or business update after the earnings release has been issued are invited to contact the company at IR@chemomab.com. About Chemomab Therapeutics Ltd. Chemomab is a clinical stage biotechnology company

First-in-Class CCL24 Neutralizing Antibody CM-101 Demonstrated a Favorable Safety Profile and Was Generally Well-Tolerated Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC), Establishing Clinical Proof-of-Concept for the Disease-Modifying Potential of CM-101 Treatment with CM-101 Led to Statistically Significant Improvements in Liver Stiffness, a Well-Validated Biomarker of Disease Progression in PSC Treatment with CM-101 Led to Statistically Significant Improvements in Pruritis and Improvements in Total Bilirubin and Liver Function Tests Positive Phase 2 Data Paves Way f

TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will report its first quarter 2024 financial results and provide a business update on May 9, 2024, at 7:00 am Eastern Time. Investors who would like to discuss the financial results or business update after the earnings release has been issued are invited to contact the company at IR@chemomab.com. About Chemomab Therapeutics Ltd.Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflam

TEL AVIV, Israel, Feb. 14, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its fourth quarter and full year 2023 financial results and providing a business update on March 7, 2024, at 7:00 am Eastern Time. Investors who would like to discuss the financial results or business update after the press release is issued are invited to contact the company at IR@chemo

─Reported Top-line Results from CM-101 Phase 2 Liver Fibrosis Trial in NASH Patients Demonstrating Safety and Positive Activity Across Multiple Fibrotic and Inflammatory Biomarkers─ ─Received FDA Clearance for CM-101 Systemic Sclerosis IND—Phase 2 Trial Expected to Open Mid-year─ ─Advancing Phase 2 PSC Trial and Enrolling Patients in Higher Dose Cohort ─ ─Extending Estimated Cash Runway Through First Half of 2024─  ─Company to Host Conference Call for Investors Today, May 11 at 8:00 am ET ─ TEL AVIV, Israel, May 11, 2023 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeu

This Webcast and Call Replaces and Supplements the Chemomab Corporate Update Originally Scheduled for April 17, 2023 TEL AVIV, Israel, April 12, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will discuss its first quarter 2023 financial results and provide a corporate update on Thursday, May 11, 2023, at 8:00 am Eastern Time.   This webcast and call replaces and s

TEL AVIV, Israel, March 29, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will provide a Corporate Update on Monday, April 17, 2023, at 8:00 am Eastern Time. This event replaces the webcast and call originally scheduled for March 31, 2023. During the event, Chemomab's management team will review recent corporate developments and conduct a live question-and-answer

TEL AVIV, Israel, March 17, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will discuss its fourth quarter and full-year 2022 financial results and provide a business update on Friday, March 31, 2023, at 8:00 am Eastern Time.  During the event, Chemomab's management team will review fourth quarter and full-year 2022 performance, discuss recent and upcoming developm

 ─Chemomab to Host Conference Call for Investors Today, November 11 at 8:00 am ET─ TEL AVIV, Israel, Nov. 11, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced financial and operating results for the third quarter ended September 30, 2022 and provided a corporate update. "We continued to make good progress in advancing our clinical programs for CM-101 during the third quarter," said

TEL AVIV, Israel, Nov. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its third quarter 2022 financial results and provide a business update on Friday, November 11, 2022 at 8:00 am Eastern Time. During the event, Chemomab's management team will review third quarter 2022 performance, discuss recent and upcoming developments and conduct a live

─Chemomab to Host Webcast and Conference Call for Investors Today, August 12 at 8:00 am ET─ TEL AVIV, Israel, Aug. 12, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced financial and operating results for the second quarter ended June 30, 2022 and provided a corporate update. "We continued to make good progress on multiple fronts in the second quarter," said Dale Pfost, PhD, Chairma

TEL AVIV, Israel, Aug. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its second quarter 2022 financial results and provide a business update on Friday, August 12, 2022 at 8:00 am Eastern Time. During the event, Chemomab's management team will review second quarter 2022 performance, discuss recent and upcoming developments and conduct a live

-- Company to Host Conference Call for Investors Today, May 12 at 8:00 am ET --  TEL AVIV, Israel, May 12, 2022  /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2022 and provided a corporate update. "During the quarter we continued to make good progress in refining and implementing revisions to our CM-101 clinical pr

TEL AVIV, Israel, May 4, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its first quarter 2022 financial results and provide a business update on Thursday, May 12, 2022.  The company will host a conference call at 8:00 am Eastern Time, which will be webcast at the link below and on the company's investor relations website. Chemomab's management

TEL AVIV, Israel, March 9, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (NASDAQ:CMMB), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced financial and operating results for the fourth quarter and year ended December 31, 2021, and provided a corporate update. 2021 Highlights: In February, announced positive results from a Phase 1b trial in patients with non-alcoholic fatty liver disease. CM-101 appeared safe and well tolerated upon multiple

TEL AVIV, Israel, March 2, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its fourth quarter and full year 2021 financial results and provide a business update on Wednesday, March 9, 2022.  The company will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day, which will be broadcast live at the link below and on the company's investor relations website at investors.chemomab.com/events. The conference call will also be available by tel